Comprehensive investigation of resveratrol as an anti-aging supplement in randomised clinical trials

En systematisk översikt samlade alla publicerade randomiserade kontrollerade studier av rent resveratrol och fann 137 studier, omfattande 104 unika RCT:er och fler än 4 800 personer. 92 studies (67 percent) reported a positive effect on their primär endpoint. 42 studies (31 percent) reported no effect. The recurring limit in almost every trial is oral bioavailability. Resveratrol is conjugated so fast by phase-II liver enzymes that plasma levels rarely reach the concentrations that drove the mouse and yeast findings. This is the single largest human RCT count for any molecule in our database. It does not settle whether resveratrol slows aging in people. It does show the molecule has real, dose-dependent effects on some cardiovascular and metabolic endpoints, and near-zero effect on others.

Of 137 RCTs identified, 92 (67 percent) showed a positive effect on the primär endpoint, and 42 (31 percent) showed none; poor bioavailability is the consistent limitation.